文献速递肿瘤 PET/CT神经核医学

[18F]MFBG PET/CT在神经母细胞瘤评估中优于[123I]MIBG SPECT/CT

[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-09

这项前瞻性单中心研究纳入40例有神经母细胞瘤病史的儿童(平均年龄6.0±3.7岁),全部同时接受[123I]MIBG SPECT/CT与[18F]MFBG PET/CT检查。在34例任一显像阳性的患者中,[18F]MFBG PET/CT检出784个病灶,[123I]MIBG SPECT/CT检出532个病灶(p<0.001);[18F]MFBG的Curie评分(11.32±8.18)也高于[123I]MIBG(7.74±7.52,p<0.001)。结论为[18F]MFBG PET/CT在小儿神经母细胞瘤评估中病灶检出率高于[123I]MIBG SPECT/CT。

要点

  • 40例有神经母细胞瘤病史的儿童同时接受[123I]MIBG SPECT/CT与[18F]MFBG PET/CT检查。
  • 34例影像阳性患者中,[18F]MFBG PET/CT检出784个病灶,[123I]MIBG SPECT/CT检出532个(p<0.001)。
  • [18F]MFBG PET/CT的Curie评分11.32±8.18高于[123I]MIBG SPECT/CT的7.74±7.52(p<0.001)。

核心结论

  • 在儿童神经母细胞瘤评估中,[18F]MFBG PET/CT的病灶检出率高于[123I]MIBG SPECT/CT。

研究设计与样本

  • 前瞻性单中心研究,纳入40例有神经母细胞瘤病史的参与者(平均年龄6.0±3.7岁)。
  • 所有儿童均接受[123I]MIBG SPECT/CT与[18F]MFBG PET/CT两种检查,记录各方法检出的病灶数与Curie评分。
  • 临床试验注册号NCT05069220(2021年9月25日回顾性注册);北京协和医院机构审查委员会批件号ZS-2514。

主要发现

  • 6例患者在[123I]MIBG与[18F]MFBG两种检查中均为阴性。
  • 34例患者中4例(11.8%)[123I]MIBG阴性而[18F]MFBG阳性,30例两种检查均阳性。
  • 在这34例患者中,[18F]MFBG PET/CT检出784个病灶,[123I]MIBG SPECT/CT检出532个病灶(p<0.001)。
  • [18F]MFBG PET/CT的Curie评分为11.32±8.18(范围1-27),高于[123I]MIBG SPECT/CT的7.74±7.52(范围0-26),p<0.001。
  • 34例影像显示活动性疾病的患者中,30例(88.2%)基于[18F]MFBG的Curie评分高于基于[123I]MIBG的评分。

关键数值与推荐

  • 病灶检出数:[18F]MFBG PET/CT 784个 vs [123I]MIBG SPECT/CT 532个(p<0.001)。
  • Curie评分:[18F]MFBG PET/CT 11.32±8.18(范围1-27) vs [123I]MIBG SPECT/CT 7.74±7.52(范围0-26),p<0.001。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Iodine 123 labeled meta-iodobenzylguanidine ([123I]MIBG) scan with SPECT/CT imaging is one of the most commonly used imaging modalities in the evaluation of neuroblastoma. [18F]-meta-fluorobenzylguanidine ([18F]MFBG) is a novel positron emission tomography (PET) tracer which was reported to have a similar biodistribution to [123I]MIBG. However, the experience of using [18F]MFBG PET/CT in the evaluation of patients with neuroblastoma is limited. This preliminary investigation aims to assess the efficacy of [18F]MFBG PET/CT in the evaluation of neuroblastomas in comparison to [123I]MIBG scans with SPECT/CT. MATERIALS AND METHODS: In this prospective, single-center study, 40 participants (mean age 6.0 ± 3.7 years) with history of neuroblastoma were enrolled. All children underwent both [123I]MIBG SPECT/CT and [18F]MFBG PET/CT studies. The number of lesions and the Curie scores revealed by each imaging method were recorded. RESULTS: Six patients had negative findings on both [123I]MIBG and [18F]MFBG studies. Four of the 34 patients (11.8%) were negative on [123I]MIBG but positive on [18F]MFBG, while 30 patients were positive on both [123I]MIBG and [18F]MFBG studies. In these 34 patients, [18F]MFBG PET/CT identified 784 lesions while [123I]MIBG SPECT/CT detected 532 lesions (p < 0.001). The Curie scores obtained from [18F]MFBG PET/CT (11.32 ± 8.18, range 1-27) were statistically higher (p < 0.001) than those from [123I]MIBG SPECT/CT (7.74 ± 7.52, range 0-26). 30 of 34 patients (88.2%) with active disease on imaging had higher Curie scores based on the [18F]MFBG study than on the [123I]MIBG imaging. CONCLUSION: [18F]MFBG PET/CT shows higher lesion detection rate than [123I]MIBG SPECT/CT in the evaluation of pediatric patients with neuroblastoma. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov : NCT05069220 (Registered: 25 September 2021, retrospectively registered); Institute Review Board of Peking Union Medical College Hospital: ZS-2514.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang P, Li T, Liu Z, et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37160439. doi:10.1007/s00259-023-06221-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。